Cereno Scientific raises SEK 60M at a premium to fund late-stage heart drug push
What's the deal? Swedish biotech Cereno ScientificDealroom has a profile for this one. Try Dealroom → (Nasdaq First North: CRNO B) has raised SEK 60 million (about $6.2 million) through a directed share issue.
The shares were sold to existing shareholders and one new investor at a roughly 4.08% premium to the latest closing price — unusual for an equity raise.
Backers include David Palm, Fredrik AdolfssonDealroom has a profile for this one. Try Dealroom →, Jan Butt, Joakim Söderström, and Ringsökalven Förvaltning AB.
Why now? Cereno is entering what it calls a value-triggering clinical phase, with two HDAC inhibitor programs heading toward Phase IIb trials in rare cardiopulmonary diseases.
Lead candidate CS1 targets pulmonary arterial hypertension; CS014 targets pulmonary hypertension linked to interstitial lung disease.
The raise follows the BIO International Convention in San Diego on June 22–25, where the company says it met current and prospective partners and gauged strong interest in its pipeline.
Cereno says the fresh capital strengthens its hand in ongoing partnering talks, letting it negotiate from a stronger position.
What could go wrong? Despite what it described as significant investor demand, Cereno capped the raise at SEK 60 million — a modest sum to push two programs through expensive late-stage trials.
Clinical-stage biotechs face high failure rates, and the partnering deals the company is betting on remain unsigned.
The signal: Dealroom classifies Cereno as a breakout-stage company, and this round leans heavily on angel backers — the kind of individual conviction that often precedes the institutional partnering deals the biotech is now chasing. Pricing the issue above market is a vote of confidence that matters more for negotiating leverage than for the modest SEK 60 million it adds to the balance sheet.
Read more: MFN
Image credit: Generated with Gemini
